Dubai, UAE, October twentieth, 2025, FinanceWire
Following current licensing frameworks and the worldwide publicity of the PLPC Platform, the American-born biotechnology system — backed by Q1 publications, filed patents, FDA-aligned audits, and UAE-based authorized and banking companions — consolidates its presence throughout Asia, Europe, and the Center East.
OGRD Alliance L.L.C-FZ, a world biotechnology group led by its Chief Scientific Officer, Oncopathologist Dr. Ramón Gutiérrez Sandoval, M.D., publicizes the growth of its PLPC-DB phospholipoproteomic module, supported by the OncoVix Program, from Dubai towards Asia and the MENA area. The initiative reinforces the group’s place as a bridge between American scientific innovation and international life-science funding.
The growth follows participation in worldwide biotechnology conferences and the formalization of producing and licensing agreements with strategic brokers and consultancies in Japan and Singapore. The Dubai hub now acts because the group’s monetary and logistical middle for Asia and the Center East.
The PLPC Platform
The proprietary PLPC (Phospholipoproteomic Complicated) integrates 4 scientific and regulatory pillars:
-
PLPC-DB, a non-cellular immunobiological module validated beneath FDA-aligned documentation for adaptive biotechnology.
-
PLPC-NX, referred to as ABIMPROSYC, a GRAS-certified dietary know-how platform synchronized with circadian and metabolic regulation.
-
STIP (Structural Traceability and Immunophenotypic Platform), making certain ex vivo validation, cross-jurisdictional reproducibility, and real-world-evidence compliance.
The platform’s scientific validation pillar is supported by 11 Tier-1 congress displays (ASCO, ESMO, SITC, CAP-25, BioJapan 2025), 5 Q1-indexed papers listed in PubMed, three worldwide patent households filed in the USA, Japan, and Australia, and two impartial pre-FDA regulatory audits confirming knowledge integrity and traceability.
OncoVix Program
The OncoVix Program documentation community encompasses a whole lot of anonymized dossiers divided into validated sub-cohorts, representing 1000’s of purposes beneath managed real-world-evidence situations — demonstrating that biotechnology originating in America can obtain measurable and reproducible outcomes assembly international requirements of security and transparency.
“Our aim has all the time been to merge ethics, proof, and scalability,” stated Dr. Ramón Gutiérrez Sandoval, Founder and Chief Scientific Officer of OGRD Alliance. “From America to Dubai and now towards Asia and MENA, OncoVix and PLPC-DB illustrate how data-driven innovation can transcend borders and advance international biotech requirements.”
